WO2010107177A3 - Composition for prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredients - Google Patents
Composition for prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredients Download PDFInfo
- Publication number
- WO2010107177A3 WO2010107177A3 PCT/KR2009/007905 KR2009007905W WO2010107177A3 WO 2010107177 A3 WO2010107177 A3 WO 2010107177A3 KR 2009007905 W KR2009007905 W KR 2009007905W WO 2010107177 A3 WO2010107177 A3 WO 2010107177A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- obesity
- present
- camphene
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
The present invention relates to a composition for prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredients. The composition comprising camphene as active ingredients according to the present invention suppresses adipocyte differentiation and reduces the body fat mass, amount of visceral fat, total cholesterol concentration and triglycerides in plasma and liver tissues, which ultimately leads to the prevention or treatment activity in obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention induces a significant reduction in fasting blood sugar and serum insulin levels to thus improve Type 2 diabetes or insulin resistance as well as metabolic diseases associated therewith. Moreover, the composition of the present invention significantly reduces the expression of nuclear transcription factors (C/EBPα and PPARγ2) and a target gene (ap2) thereof, which play pivotal roles in generation of adipose tissues in visceral adipose tissues, thereby exerting suppression effects on the amount of visceral fat, and the expression of cytokine (TNF-α or IL-6) that activates inflammation, thereby improving chronic inflammatory activation induced by obesity in visceral adipose tissues. Further, the composition of the present invention increases the expression of UCP (UCP1 or UCP3) genes that regulate heat generation in vivo, thereby improving the phenomenon of inhibition on heat generation induced by obesity in visceral adipose tissues.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/256,461 US8552069B2 (en) | 2009-03-18 | 2009-12-29 | Method for treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0022937 | 2009-03-18 | ||
KR1020090022937A KR101050429B1 (en) | 2009-03-18 | 2009-03-18 | Composition for the prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphor as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010107177A2 WO2010107177A2 (en) | 2010-09-23 |
WO2010107177A3 true WO2010107177A3 (en) | 2010-11-18 |
Family
ID=42740082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/007905 WO2010107177A2 (en) | 2009-03-18 | 2009-12-29 | Composition for prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredients |
Country Status (3)
Country | Link |
---|---|
US (1) | US8552069B2 (en) |
KR (1) | KR101050429B1 (en) |
WO (1) | WO2010107177A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9328330B2 (en) * | 2011-01-10 | 2016-05-03 | Sami Labs Limited | Anti-obesity potential of Calebin A |
CA2851717A1 (en) * | 2011-01-10 | 2013-07-25 | Muhammed Majeed | Anti-obesity potential of calebin a |
KR101309967B1 (en) * | 2011-04-19 | 2013-09-27 | 주식회사 고암바이오알앤디수 | Pharmaceutical composition for treating or preventing fatty liver disease comprising extract of Cyperi Rhizoma |
GR20110100564A (en) * | 2011-09-29 | 2013-04-18 | Halldale Ventures Limited, | Camphene reduces plasma cholesterol and triglycerides |
US20130164396A1 (en) * | 2011-12-21 | 2013-06-27 | Shorong Shii LIOU | Angelica extract for treating fatty liver disease |
WO2014058301A1 (en) | 2012-10-12 | 2014-04-17 | N.V. Nutricia | Infant nutrition with lipid globules to increase energy expenditure and metabolic flexibility later in life |
DK3091973T3 (en) | 2013-11-01 | 2018-11-05 | Nutricia Nv | LIPID COMPOSITION FOR IMPROVING BODY COMPOSITION DURING GROWTH |
TW201521752A (en) * | 2013-12-05 | 2015-06-16 | Univ Nat Taiwan Normal | Application of antrodia camphorate in anti-obesity activity and method thereof |
KR20160001935A (en) | 2014-06-30 | 2016-01-07 | 원광대학교산학협력단 | A composition comprising the extract of black current for preventing, improving or treating metabolic syndrome |
CN104127394A (en) * | 2014-07-15 | 2014-11-05 | 沈祥春 | Application of above one of alpha-pinene, beta-pinene, 1,8-eudesmol and camphene in preparation of human blood vessel endothelial cell damage treatment medicines |
KR101669140B1 (en) * | 2015-04-28 | 2016-10-26 | (주)케어젠 | Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof |
PL3361885T3 (en) | 2015-10-15 | 2019-11-29 | Nutricia Nv | Infant formula with special lipid architecture for promoting healthy growth |
CN110177467A (en) | 2016-12-09 | 2019-08-27 | N·V·努特里奇亚 | For improving the alimentation composition of cell membrane |
CN107737121A (en) * | 2017-11-16 | 2018-02-27 | 中国药科大学 | Corylin is used for the purposes for preparing the medicine for the treatment of atherosclerosis |
CN107714699A (en) * | 2017-11-16 | 2018-02-23 | 中国药科大学 | Hydrochloric acid lycorine is used for the medical usage for preparing medicine |
US20230142208A1 (en) * | 2020-03-23 | 2023-05-11 | Czap Research And Development, Llc. | Oral terpene cyclodextrin inclusion complex vehicles |
KR102242195B1 (en) * | 2020-06-16 | 2021-04-21 | 주식회사 웰니스바이오 | Composition for improving, preventing or treating non-alcoholic liver disease and preparation method thereof |
WO2023121610A1 (en) * | 2021-12-21 | 2023-06-29 | İstanbul Medi̇pol Üni̇versi̇tesi̇ | Development of original microemulsion formulations effective against fatty liver from standardized salvia triloba extracts |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5990177A (en) * | 1996-09-18 | 1999-11-23 | Codon Pharmaceuticals, Inc. | Treatment of diseases mediated by the nitric oxide/cGMP/protein kinase G pathway |
US6455078B1 (en) * | 2000-10-18 | 2002-09-24 | Tzu-Sheng Wu | Medicinal herbal composition for treating liver diseases and HIV |
US20040151792A1 (en) * | 2001-06-20 | 2004-08-05 | Tripp Matthew L. | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
US20040247669A1 (en) * | 2003-02-04 | 2004-12-09 | Gin Jerry B. | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth |
KR20050071605A (en) * | 2002-10-21 | 2005-07-07 | 메타프로테오믹스, 엘엘씨 | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101143172A (en) * | 2007-08-30 | 2008-03-19 | 尹克山 | Traditional Chinese medicine for treating obesity in children |
-
2009
- 2009-03-18 KR KR1020090022937A patent/KR101050429B1/en active IP Right Grant
- 2009-12-29 US US13/256,461 patent/US8552069B2/en not_active Expired - Fee Related
- 2009-12-29 WO PCT/KR2009/007905 patent/WO2010107177A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5990177A (en) * | 1996-09-18 | 1999-11-23 | Codon Pharmaceuticals, Inc. | Treatment of diseases mediated by the nitric oxide/cGMP/protein kinase G pathway |
US6455078B1 (en) * | 2000-10-18 | 2002-09-24 | Tzu-Sheng Wu | Medicinal herbal composition for treating liver diseases and HIV |
US20040151792A1 (en) * | 2001-06-20 | 2004-08-05 | Tripp Matthew L. | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
KR20050071605A (en) * | 2002-10-21 | 2005-07-07 | 메타프로테오믹스, 엘엘씨 | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
US20040247669A1 (en) * | 2003-02-04 | 2004-12-09 | Gin Jerry B. | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth |
Non-Patent Citations (1)
Title |
---|
STRAZNICKY, N. E. ET AL.: "Effects of Dietary Weight Loss on Sympathetic Activity and Cardiac Risk Factors Associated with the Metabolic Syndrome", THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 90, no. 11, 2005, pages 5998 - 6005 * |
Also Published As
Publication number | Publication date |
---|---|
US8552069B2 (en) | 2013-10-08 |
KR101050429B1 (en) | 2011-07-19 |
WO2010107177A2 (en) | 2010-09-23 |
US20120035274A1 (en) | 2012-02-09 |
KR20100104490A (en) | 2010-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010107177A2 (en) | Composition for prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredients | |
Feng et al. | ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: an updated review | |
Tanaka et al. | Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine-and choline-deficient diet | |
Kuo et al. | Positive effect of curcumin on inflammation and mitochondrial dysfunction in obese mice with liver steatosis | |
Kim et al. | Antihyperglycemic and anti-inflammatory effects of standardized Curcuma xanthorrhiza Roxb. extract and its active compound xanthorrhizol in high-fat diet-induced obese mice | |
Duvnjak et al. | Therapy of nonalcoholic fatty liver disease: current status | |
Choi et al. | Piperine reverses high fat diet-induced hepatic steatosis and insulin resistance in mice | |
Zhou et al. | Preventive efficiency of green tea and its components on nonalcoholic fatty liver disease | |
Lim et al. | Modulation of adiponectin as a potential therapeutic strategy | |
Liang et al. | Protective roles and mechanisms of Dendrobium officinal polysaccharides on secondary liver injury in acute colitis | |
Yu et al. | Fibroblast growth factor 21 (FGF21) ameliorates collagen-induced arthritis through modulating oxidative stress and suppressing nuclear factor-kappa B pathway | |
Hossain et al. | The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin | |
Xu et al. | Effect and possible mechanisms of dioscin on ameliorating metabolic glycolipid metabolic disorder in type-2-diabetes | |
Ho et al. | The Monascus metabolite monacolin K reduces tumor progression and metastasis of Lewis lung carcinoma cells | |
Kuo et al. | Ergostatrien-3β-ol from Antrodia camphorata inhibits diabetes and hyperlipidemia in high-fat-diet treated mice via regulation of hepatic related genes, glucose transporter 4, and AMP-activated protein kinase phosphorylation | |
Chen et al. | Lipid-lowering effects of Danhong injection on hyperlipidemia rats | |
Chen et al. | Hypolipidemic effect of oleanolic acid is mediated by the miR‐98‐5p/PGC‐1β axis in high‐fat diet‐induced hyperlipidemic mice | |
Wada et al. | Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions | |
Zhang et al. | Metabolomics for biomarker discovery in fermented black garlic and potential bioprotective responses against cardiovascular diseases | |
Noh et al. | Inhibitory effect of a Cirsium setidens extract on hepatic fat accumulation in mice fed a high-fat diet via the induction of fatty acid β-oxidation | |
Jia et al. | Fuzheng Huayu recipe prevents nutritional fibrosing steatohepatitis in mice | |
Lin et al. | Aerobic exercise decreases chemerin/CMKLR1 in the serum and peripheral metabolic organs of obesity and diabetes rats by increasing PPARγ | |
Jung et al. | Protectin DX suppresses hepatic gluconeogenesis through AMPK-HO-1-mediated inhibition of ER stress | |
Wan et al. | PGC1α protects against hepatic steatosis and insulin resistance via enhancing IL10‐mediated anti‐inflammatory response | |
Ying et al. | Pentamethylquercetin reduces fat deposition via Sirt1-mediated pathways in male obese mice induced by a high fat diet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09841961 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13256461 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09841961 Country of ref document: EP Kind code of ref document: A2 |